Back
Non classé
1 min read

[Newsletter- 11] NEWS/INFOS

  • Bertrand Fabien
  • Author Bertrand Fabien
  • Published 3 janvier 2021

Related Posts

XENOTHERA strengthens its position in oncology and announces several clinical advances and scientific publications

October, 2025. Nantes-based biotech company XENOTHERA is accelerating its developments in oncology with several multispecific glyco-humanized antibody (GH-pAb) programs. The company today announces new clinical milestones and major publications

Read More

XENOTHERA confirms progress in the treatment of peripheral T-cell lymphoma (PTCL) through its LIS22 antibody

June, 2025, Nantes-based biotech XENOTHERA confirms the value of its LIS22 antibody in the treatment of peripheral T-cell lymphomas (PTCL). The PALT1 clinical trial (NCT06495723) has just passed a new milestone

Read More

XENOTHERA reports to ASCO on the clinical trial of its first anti-cancer drug, XON7, and announces a financing agreement with BPI France

June, 2024. During its participation in ASCO, XENOTHERA….

Read More

XENOTHERA

21 rue La Nouë de Fer, 44200 Nantes, France

contact@xenothera.com

Media : xenothera@akkanto.fr
Linkedin-in